Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
The recent decision in Europe to not recommend Amsterdam Molecular Therapeutics’ (AMT’s) gene therapy Glybera for approval is the latest in a string of failures for this segment. Details on AMT’s uphill battle with getting the drug approved can be read here and may signal to other developers what to expect. While the science behind gene therapy have come a long way, proving efficacy and navigating the regulatory pathway remain roadblocks. Had AMT received the green light for Glybera, it would have become the first gene therapy approved outside of China. The only gene therapy currently on the market is Shenzhen SiBiono GeneTech’s Gendicine, which received the go-ahead in October 2003 for head and neck squamous cell carcinoma. But one report predicts that the gene therapy market will reach $316 million by 2015 driven by high demand. What are your predictions for the gene therapy market?